The first-in-class complement factor D inhibitor danicopan (Voydeya) has been approved by the European Commission as an add-on agent for certain patients with the rare disease paroxysmal nocturnal ...

TSP-1 reduced C3 and C5 cleavage and formation of the membrane attack complex, attenuating complement-mediated injury in AAV models. Complement activation is a relevant driver in the pathomechanisms ...

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, severe, and potentially life-threatening condition. Treatments targeting the complement pathway have revolutionized its management but have ...

Atypical haemolytic uremic syndrome (aHUS) is an uncommon, yet potentially life‐threatening disorder predominantly characterised by dysregulation of the alternative complement pathway. Unlike the more ...

Patients who are taking complement inhibitors may still experience breakthrough hemolysis associated with respiratory viral infections. Patients with PNH should be closely monitored for signs of ...

Please provide your email address to receive an email when new articles are posted on . Registry data showed efficacy of ravulizumab was similar to that of eculizumab. No unexpected adverse events ...

Please provide your email address to receive an email when new articles are posted on . Researchers reviewed the efficacy of ravulizumab based on 2-year data from two phase 3, single-arm studies. eGFR ...

SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (OMER) today reported that clinical trial site activation for enrollment is underway for the company’s Phase 3 program evaluating zaltenibart in ...